What is the 13F Pro Quality Score for HIMS?

13F Pro ranks Hims & Hers Health, Inc. (HIMS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HIMS's current score at https://13fpro.ai/research/HIMS (free sign-up required for the full ranking).

Where does 13F Pro source HIMS data?

All Hims & Hers Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Hims & Hers Health, Inc. files with the SEC under CIK 1773751. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HIMS in?

Hims & Hers Health, Inc. (HIMS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HIMS research updated on 13F Pro?

HIMS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Hims & Hers Health, Inc.(HIMS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1773751 HIMS stock profile & AI dashboard →

13F Pro Quality Score

50.9/100

Rank #1,430 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.7/100

Profitability

29.0/100

Balance Sheet

41.0/100

Earnings Quality

30.0/100

Free Cash Flow

50.1/100

Institutional Flow

5.6/100

Revenue Scale

65.2/100

Dilution Risk

23.7/100

HIMS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Hims & Hers Health, Inc. (HIMS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HIMS at 50.9/100 on a 32-signal composite quality model, placing it at rank #1,430 of 2,879 stocks — the top half of the AI-ranked universe. HIMS scores in the top quartile across revenue growth (93.7). Areas of concern include institutional flow (5.6) and profitability (29.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Hims & Hers Health, Inc. reports quarterly revenue of $608.1M, net income of $-92.1M, free cash flow of $53.1M. Top institutional holders of HIMS by reported 13-F value include BlackRock,, SUSQUEHANNA INTERNATIONAL GROUP, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. HIMS trades on the NYSE exchange and files with the SEC under CIK 1773751. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HIMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hims & Hers Health, Inc. directly from SEC EDGAR. Hims & Hers Health, Inc.'s 13F Pro composite quality score has ranged between 8 and 85 since 2022, currently 50.9 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$608.1M

Net Income

Q1 2026

$-92.1M

Free Cash Flow

Q1 2026

$53.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+59.0% YoY

$2.35BFY 2025

FY19 $82.6MFY22 $526.9MFY24 $1.48BFY25 $2.35B

Net Income

+1.8% YoY

$128.4MFY 2025

FY19 $-72.1MFY22 $-65.7MFY24 $126.0MFY25 $128.4M

Operating Income

+70.6% YoY

$105.6MFY 2025

FY19 $-74.4MFY22 $-68.7MFY24 $61.9MFY25 $105.6M

EPS (Diluted)

-3.8% YoY

$0.51FY 2025

FY19 $-2.07FY22 $-0.32FY24 $0.53FY25 $0.51

Total Assets

+204.5% YoY

$2.15BFY 2025

FY19 $204.8MFY22 $366.3MFY24 $707.5MFY25 $2.15B

Total Debt

—FY 2025

FY19 $1.5MFY22 —FY24 —FY25 —

Op. Cash Flow

+19.5% YoY

$300.0MFY 2025

FY19 $-74.9MFY22 $-26.5MFY24 $251.1MFY25 $300.0M

Metric	FY 2025	FY 2024	FY 2022	FY 2019	FY 2018
Revenue	$2.35B +59.0%	$1.48B +180.2%	$526.9M +538.2%	$82.6M	—
Net Income	$128.4M +1.8%	$126.0M +291.9%	$-65.7M +8.9%	$-72.1M	—
Operating Income	$105.6M +70.6%	$61.9M +190.1%	$-68.7M +7.7%	$-74.4M	—
EPS (Diluted)	$0.51 -3.8%	$0.53 +265.6%	$-0.32 +84.5%	$-2.07	—
Total Assets	$2.15B +204.5%	$707.5M +93.1%	$366.3M +78.9%	$204.8M	—
Total Debt	—	—	—	$1.5M	—
Operating Cash Flow	$300.0M +19.5%	$251.1M +1046.4%	$-26.5M +64.6%	$-74.9M	—

AI Insight: HIMS Financial Trends

HIMS swung to Q1 2026 operating loss of $78M after five consecutive profitable quarters, signaling operational deterioration despite flat revenue.

• Revenue grew 92% from Q2 2024 ($316M) to Q1 2026 ($608M), but flattened sequentially Q4 2025–Q1 2026 (-1.6%).

• Operating income collapsed to -$78M in Q1 2026 from $9M in Q4 2025; net income swung to -$92M loss.

• Operating cash flow remained positive at $89M in Q1 2026, but net income loss and Op CF volatility (range $-19M to $149M) raise sustainability concerns.

⚠ Operating margin compressed sharply to -12.8% in Q1 2026 vs. +1.5% in Q4 2025 — steepest single-quarter deterioration.

⚠ Equity declined 18% from $563M (Q2 2025 peak) to $446M (Q1 2026), reflecting cumulative losses and capital erosion.

AI Insight: HIMS Ratio Trends

Hims swung to a -1.3% operating margin on a TTM basis, reversing nine quarters of profitability and signaling a structural shift in unit economics or cost structure.

• Operating margin collapsed from 9.9% in Q1 2025 to -12.9% in Q1 2026, a 22.8 percentage-point decline in one year.

• ROIC deteriorated from 42.2% in Q1 2025 to -70.2% in Q1 2026, erasing all capital efficiency gains from prior quarters.

• Net profit margin turned negative at -15.2% in Q1 2026 versus 8.4% in Q1 2025, destroying bottom-line profitability.

⚠ TTM ROA has turned deeply negative (-0.6%) after consistently positive returns through Q4 2025, suggesting asset base misdeployment or major write-downs.

⚠ Deterioration accelerated in second half 2025 (Q3–Q4) before Q1 2026 collapse; clarify whether Q1 2026 is seasonal anomaly or trend.

Get alerted when HIMS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Hims & Hers Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HIMS

BlackRock, Inc.
$546.8M26,337,158 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$266.8M12,850,900 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$219.4M10,567,200 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$211.4M10,183,813 sh
VANGUARD CAPITAL MANAGEMENT LLC
$193.9M9,339,711 sh
MORGAN STANLEY
$184.5M8,889,088 sh
JANE STREET GROUP, LLC
$171.7M8,271,300 sh
STATE STREET CORP
$154.9M7,460,023 sh
Defiance ETFs, LLC
$154.1M7,424,258 sh
CITADEL ADVISORS LLC
$143.6M6,915,700 sh

Fund	Value	Shares
BlackRock, Inc.	$546.8M	26,337,158
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$266.8M	12,850,900
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$219.4M	10,567,200
VANGUARD PORTFOLIO MANAGEMENT LLC	$211.4M	10,183,813
VANGUARD CAPITAL MANAGEMENT LLC	$193.9M	9,339,711
MORGAN STANLEY	$184.5M	8,889,088
JANE STREET GROUP, LLC	$171.7M	8,271,300
STATE STREET CORP	$154.9M	7,460,023
Defiance ETFs, LLC	$154.1M	7,424,258
CITADEL ADVISORS LLC	$143.6M	6,915,700

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HIMS on your watchlist

Track score changes the day Hims & Hers Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HIMS a good stock to buy?

13F Pro's AI-powered analysis of Hims & Hers Health, Inc. (HIMS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HIMS are available on the HIMS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HIMS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HIMS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Hims & Hers Health, Inc.'s investment landscape.